Accordingly, inhibition of the CD39/CD73/adenosine pathway with eAdo receptor antagonists, anti‐CD39 or ‐CD73 antibodies has demonstrated promising efficacy in the treatment of cancer.3, 4. The gene discussed is ENTPD1; the disease is cancer.